Novel therapies in myeloid neoplasms show limited benefit and increased costs over 15 years of follow-up in Southern Finland.

Despite a decreasing trend, there were no differences in the distribution of total cycle of HDC, induction cycles and consolidation cycles by diagnostic periods (Table 1 ).

also in 47,180 other papers